ALDA Enters National Phase with New Patent Application
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V, APCSF:OTCQB) (the “Company” or “ALDA”) has filed its patent application, “Antiseptic Compositions for the Treatment of Infections”, with the US Patent and Trademark Office (Serial #12/933,358). The application, first submitted to the Canadian Intellectual Property office for review in March, 2008 under the Patent Cooperation Treaty, seeks protection for the composition and preparation of T36® formulations that also contain steroids, anesthetics or analgesics for use on topical infections and, in particular, inflamed infections. Typically, infections with associated inflammation are treated with separate antiseptic and anti-inflammatory preparations. The new T36® formulations combine these properties into a single treatment, making the prescription process easier for the physician and the application easier for the patient. Submissions to the European and Canadian patent offices are also planned. This patent is the third in a series of patents providing protection for the T36® technology that have been issued or are pending.
The first patent, providing protection for the composition and production methods for ALDA's T36® formulation until August 20, 2022, is:
· issued in Australia (#2002322916), the US (#7,338,927) and China (#ZL02829642.7),
· allowed and pending in Canada (Patent Application #2,495,938) and
· pending in the EU (Patent Application #02754054.1-2113).
The second patent, providing protection for the use of T36® as a component of a personal lubricant, in a method of preventing or reducing the transmission of a sexually transmitted diseases including Herpes, Chlamydia and HIV and for use in sanitizers and cleansers in creams, ointments and wipes until August 20, 2022, is
· issued in Australia (#2007237333) and the US (#7,560,422),
· allowed and is pending in Canada (Patent Application #2,495,938) and
· pending in China (Chinese Divisional Patent Application #200710142798.3) and the EU (Patent Application #02754054.1-2113).
According to Dr. Terrance Owen, President & CEO, “Intellectual property protection is one of the key assets of emerging pharmaceutical companies. We are committed to building the Company’s patent portfolio so that we have the protection required in the main international markets that we are targeting with the therapeutic products derived from the T36® technology”.
